Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Phenylpiracetam hydrazide and Pramiracetam — mechanism, side effects, legal status, and pricing.
Phenylpiracetam hydrazide is a non-peptide racetam-class small molecule — specifically a pyrrolidinone acetohydrazide in which the terminal carboxamide of phenylpiracetam (fonturacetam) is replaced by a carbohydrazide group. First synthesized in 1980 by a Russian medicinal-chemistry group screening 4-phenyl-2-pyrrolidinone derivatives for anticonvulsant activity, it has never been approved as a drug in any jurisdiction and has no human clinical trial data. The parent compound phenylpiracetam is explicitly listed on the WADA Prohibited List under S6.A (Non-Specified Stimulants); the hydrazide analog's own it is not on the WADA Prohibited List (only beta-2 agonists are prohibited, Category S3). It is sold by gray-market research-chemical vendors labeled 'not for human consumption.'
Pramiracetam is a non-peptide synthetic racetam-class nootropic (2-oxopyrrolidone/pyrrolidinone acetamide derivative) with CAS 68497-62-1 and molecular formula C14H27N3O2. It was previously approved and marketed in Italy and some Eastern European countries under brand names Pramistar, Neupramir, and Remen for memory/attention deficits in aging-associated dementias; Italian authorization was revoked in 2020 at manufacturer request. It is not FDA-approved in the United States, where it is sold only as an unapproved gray-market research chemical. The related racetam phenylpiracetam is explicitly listed on the WADA Prohibited List as an S6 stimulant; pramiracetam itself is not explicitly named, leaving its status under WADA's 'similar structure/effect' catch-all unresolved.
Phenylpiracetam hydrazide
Pramiracetam
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Phenylpiracetam hydrazide
No pricing data yet.
Check Phenylpiracetam hydrazide prices →Pramiracetam
No pricing data yet.
Check Pramiracetam prices →COA corpus from Disclosed Labs — independently tested batches only.
Phenylpiracetam hydrazide
2
COAs
99.4%
Avg purity
2
Labs
Pramiracetam
2
COAs
99.9%
Avg purity
2
Labs
No human clinical trials have been conducted; no ClinicalTrials.gov record or DrugBank entry exists. The sole preclinical finding is from the 1980 Glozman et al. synthesis paper: an ED<sub>50</sub> of approximately 310 mg/kg for seizure protection in a rodent electroshock assay (species, strain, sex, and route not fully recoverable from accessed sources). No published human toxicology, LD<sub>50</sub>, pharmacokinetics, or adverse-event data were located for this compound.
Human data consist of a handful of small older trials (1985–1996): healthy-volunteer pharmacokinetic studies, a scopolamine-induced-amnesia challenge study, a placebo-controlled trial in young males with head-injury/anoxia-related memory deficits (400 mg TID improved delayed recall), and a small dose-finding trial in Alzheimer's disease that found no convincing benefit at doses up to 4,000 mg. A scopolamine-challenge study (600 mg BID × 10 days) showed partial mitigation of induced amnesia in healthy young and older male volunteers. No modern (post-2000) randomized controlled trials were located. Preclinical findings: in rats, 7.5 and 15 mg/kg/day × 7 weeks significantly improved reference (long-term) memory on a 16-arm radial maze but did not affect working memory; 300 mg/kg i.p. increased cortical nitric oxide synthase activity ~20% (synergistic ~40% increase with lithium pretreatment); moderate protection against hypobaric-hypoxia-induced deficits in immature rats.
Phenylpiracetam hydrazide and Pramiracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs